In this study, we describe the development of DELFI-TF, a fragmentomics approach designed to measure tumor burden quantitatively, and demonstrate its potential for longitudinal disease monitoring in patients with cancer without the requirement of detecting mutations in tumor tissue. This evidence concerns the gene TF and cancer.